CoChat

Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial

Open access
Anker, Stefan D., Butler, Javed, Filippatos, Gerasimos, Shahzeb Khan, Muhammad, Ferreira, João Pedro, Bocchi, Edimar, Böhm, Michael, Brunner-La Rocca, Hans Pieter, Choi, Dong-Ju, Chopra, Vijay, Chuquiure, Eduardo, Giannetti, Nadia, Gomez-Mesa, Juan Esteban, Janssens, Stefan, Januzzi, James L., Gonzalez-Juanatey, Jose R., Merkely, Bela, Nicholls, Stephen J., Perrone, Sergio V., Piña, Ileana L., Ponikowski, Piotr, Senni, Michele, Seronde, Marie-France, Sim, David, Spinar, Jindrich, Squire, Iain, Taddei, Stefano, Tsutsui, Hiroyuki, Verma, Subodh, Vinereanu, Dragos, Zhang, Jian, Jamal, Waheed, Schnaidt, Sven, Schnee, Janet M., Brueckmann, Martina, Pocock, Stuart J., Zannad, Faiez, Packer, Milton, EMPEROR-Preserved Trial Committees and Investigators · 2020 · European Journal of Heart Failure
Cited by 133

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Aims: EMPEROR-Preserved is an ongoing trial evaluating the effect of empagliflozin in patients with heart failure with preserved ejection fraction (HFpEF). This report describes the baseline characteristics of the EMPEROR-Preserved cohort and compares them with patients enrolled in prior HFpEF trials. Methods and results: EMPEROR-Preserved is a phase III randomized, international, double-blind, parallel-group, placebo-controlled trial in which 5988 symptomatic HFpEF patients [left ventricular ejection fraction (LVEF) >40%] with and without type 2 diabetes mellitus (T2DM) have been enrolled. Patients were required to have elevated N-terminal pro B-type natriuretic peptide (NT-proBNP) concentrations (i.e. >300 pg/mL in patients without and >900 pg/mL in patients with atrial fibrillation) along with evidence of structural changes in the heart or documented history of heart failure hospitalization. Among patients enrolled from various regions (45% Europe, 11% Asia, 25% Latin America, 12% North America), the mean age was 72 ± 9 years, 45% were women. Almost all patients had New York Heart Association class II or III symptoms (99.6%), and 23% had prior heart failure hospitalization within 12 months. Thirty-three percent of the patients had baseline LVEF of 41–50%. The mean LVEF (54 ± 9%) was slightly lower while the median NT-proBNP [974 (499–1731) pg/mL] was higher compared with previous HFpEF trials. Presence of comorbidities such as diabetes (49%) and chronic kidney disease (50%) were common. The majority of the patients were on angiotensin-converting enzyme inhibitors/angiotensin receptor blockers/angiotensin receptor–neprilysin inhibitors (80%) and beta-blockers (86%), and 37% of patients were on mineralocorticoid receptor antagonists. Conclusion: When compared with prior trials in HFpEF, the EMPEROR-Preserved cohort has a somewhat higher burden of comorbidities, lower LVEF, higher median NT-proBNP and greater use of mineralocorticoid receptor antagonists at baseline. Results of the EMPEROR-Preserved trial will be available in 2021.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ejhf.2064

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 133

Metadata

Authors
Anker, S. D., Butler, J., Filippatos, G., Shahzeb Khan, M., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H. P., Choi, D.-J., Chopra, V., Chuquiure, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., Piña, I. L., Ponikowski, P., Senni, M., Seronde, M.-F., Sim, D., Spinar, J., Squire, I., Taddei, S., Tsutsui, H., Verma, S., Vinereanu, D., Zhang, J., Jamal, W., Schnaidt, S., Schnee, J. M., Brueckmann, M., Pocock, S. J., Zannad, F., Packer, M., & EMPEROR-Preserved Trial Committees and Investigators
Venue
European Journal of Heart Failure
Published
2020-12-01
Volume
22
Issue
12
Pages
2383-2392
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W3107459439
Cited by
133
References
14
FWCI
13.13
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial. https://app.cochat.ai/papers/10.1002/ejhf.2064
The paper
Anker, S. D., Butler, J., Filippatos, G., Shahzeb Khan, M., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner-La Rocca, H. P., Choi, D.-J., Chopra, V., Chuquiure, E., Giannetti, N., Gomez-Mesa, J. E., Janssens, S., Januzzi, J. L., Gonzalez-Juanatey, J. R., Merkely, B., Nicholls, S. J., Perrone, S. V., . . . EMPEROR-Preserved Trial Committees and Investigators. (2020). Baseline Characteristics of Patients with Heart Failure with Preserved Ejection Fraction in the EMPEROR-Preserved Trial. European Journal of Heart Failure. https://doi.org/10.1002/ejhf.2064

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.